Silas Inman

Long-term results of a phase 2 study (NCT02211131) revealed consistent efficacy at 5 years with talimogene laherparepvec in stage IIIB to IVM1a melanoma.

Results of a phase 3 study appear to indicate better progression-free and overall survival outcomes with camrelizumab and rivoceranib vs sorafenib in unresectable hepatocellular carcinoma.

A randomized phase 3 trial presented at 2022 ESMO revealed better progression-free survival outcomes with tumor-infiltrating lymphocytes vs ipilimumab in stage IIIC/IV unresectable, treatment-refractory melanoma.

Treatment with the oral VEGFR2 inhibitor rivoceranib appears to induce responses in recurrent or metastatic adenoid cystic carcinoma.

Patients with very high-risk renal cell carcinoma experienced a notable relapse-free survival benefit vs placebo following treatment with everolimus.

Radiotherapy can be avoided after surgery in certain patients with low-grade luminal A breast cancer who have low Ki67 expression and no positive lymph nodes, according to data from 2022 ASCO.

The phase 3 DESTINY-Breast04 trial using fam-trastuzumab deruxtecan-nxki showed a reduction in the risk of disease recurrence or death for patients with HER2-low, hormone receptor–positive metastatic breast cancer.

A Claudin18.2–specific CAR T-cell therapy has shown promise in the treatment of patients with heavily pretreated advanced gastric and pancreatic adenocarcinoma whose disease expresses the marker.

An acceptable safety reported at a follow-up analysis of the phase 3 DESTINY-Breast03 study has reinforced use of fam-trastuzumab deruxtecan-nxki for patients with HER2-positive unresectable or metastatic breast cancer

Phase 2 data indicate promising responses are possible with fixed-duration glofitamab in patients with heavily pretreated, highly refractory large B-cell lymphoma.

Results of the phase 3 EVEREST trial show adjuvant everolimus improved recurrence-free survival for patients with very high-risk renal cell carcinoma.

Use of circulating tumor DNA to guide adjuvant treatment planning for patients with resectable colon cancer led to fewer patients receiving chemotherapy while maintaining outcomes, according to the DYNAMICS study.

Results of the GEMSTONE-201 study demonstrate complete responses were achieved in roughly one-third of patients with relapsed or refractory extranodal natural killer/T-cell lymphoma who were treated with sugemalimab.

CYNK-101 plus standard frontline chemotherapy, trastuzumab, and pembrolizumab has received a fast track designation from the FDA for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Patients with large B-cell lymphoma who were previously excluded from investigations experienced increased efficacy with the use of axicabtagene ciloleucel.

Induction and consolidation with daratumumab, ixazomib, lenalidomide, and dexamethasone was able to induce minimal residual disease in a subset of patients with transplant-eligible newly diagnosed multiple myeloma and standard-risk disease.

Patients with autologous stem cell transplant–ineligible relapsed/refractory diffuse large B-cell lymphoma appear to benefit from treatment with tafasitamab and lenalidomide.

Patients with newly diagnosed multiple myeloma who are non-transplant eligible and intermediate-fit and who received a less toxic regimen of ixazomib, daratumumab, and low-dose dexamethasone demonstrated higher rates of objective response.

The first-in-class inhibitor of connective tissue growth factor activity is being explored in combination with neoadjuvant gemcitabine and nab-paclitaxel as a potential method for downgrading unresectable locally advanced pancreatic cancer.

Scott Gottlieb, MD, spoke about the spread of the novel coronavirus (COVID-19) during the keynote address at the 37th Annual Miami Breast Cancer Conference®.

CC-93269 showed encouraging signs of dose-dependent efficacy with a safety profile that continues to be refined for patients with heavily pretreated relapsed/refractory multiple myeloma.

The CAR T-cell therapy axicabtagene ciloleucel induced a median overall survival of 25.8 months for patients with refractory large B-cell lymphoma.